Cybin Inc
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anx… Read more
Cybin Inc (CYBN) - Net Assets
Latest net assets as of September 2025: $139.00 Million USD
Based on the latest financial reports, Cybin Inc (CYBN) has net assets worth $139.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($181.25 Million) and total liabilities ($42.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $139.00 Million |
| % of Total Assets | 76.69% |
| Annual Growth Rate | 130.98% |
| 5-Year Change | 16281.22% |
| 10-Year Change | N/A |
| Growth Volatility | 1910.98 |
Cybin Inc - Net Assets Trend (2017–2025)
This chart illustrates how Cybin Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cybin Inc (2017–2025)
The table below shows the annual net assets of Cybin Inc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $237.20 Million | -18.75% |
| 2024-03-31 | $291.93 Million | +283.33% |
| 2023-03-31 | $76.16 Million | -11.57% |
| 2022-03-31 | $86.12 Million | +5847.38% |
| 2021-03-31 | $1.45 Million | 0.00% |
| 2020-03-31 | $1.45 Million | +266.84% |
| 2019-03-31 | $394.73K | -10.34% |
| 2018-03-31 | $440.25K | +50.37% |
| 2017-03-31 | $292.78K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cybin Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33924078400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $464.36 Million | 195.77% |
| Other Comprehensive Income | $-7.23 Million | -3.05% |
| Other Components | $119.44 Million | 50.35% |
| Total Equity | $237.20 Million | 100.00% |
Cybin Inc Competitors by Market Cap
The table below lists competitors of Cybin Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ho Tung Chemical Corp
TW:1714
|
$202.24 Million |
|
ANY Security Printing PLC
BUD:ANY
|
$202.31 Million |
|
Eugene Inv&Sec
KO:001200
|
$202.34 Million |
|
The RMR Group Inc
F:26R
|
$202.36 Million |
|
Net Lease Office Properties
NYSE:NLOP
|
$202.21 Million |
|
Raymond Lifestyle Ltd
NSE:RAYMONDLSL
|
$202.07 Million |
|
Warpaint London PLC
OTCQX:WPNTF
|
$201.97 Million |
|
Zhejiang Zomax Transmission
SHG:603767
|
$201.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cybin Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 291,927,000 to 237,200,000, a change of -54,727,000 (-18.7%).
- Net loss of 113,137,000 reduced equity.
- New share issuances of 20,487,000 increased equity.
- Other comprehensive income decreased equity by 69,762,000.
- Other factors increased equity by 107,685,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-113.14 Million | -47.7% |
| Share Issuances | $20.49 Million | +8.64% |
| Other Comprehensive Income | $-69.76 Million | -29.41% |
| Other Changes | $107.69 Million | +45.4% |
| Total Change | $- | -18.75% |
Book Value vs Market Value Analysis
This analysis compares Cybin Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 248.76x to 4.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | $0.02 | $5.25 | x |
| 2019-03-31 | $0.03 | $5.25 | x |
| 2020-03-31 | $0.03 | $5.25 | x |
| 2021-03-31 | $144800.00 | $5.25 | x |
| 2022-03-31 | $0.51 | $5.25 | x |
| 2023-03-31 | $0.41 | $5.25 | x |
| 2024-03-31 | $1.57 | $5.25 | x |
| 2025-03-31 | $1.28 | $5.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cybin Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-47.70%) is above the historical average (-329.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -43.38% | 0.00% | 0.00x | 1.51x | $-156.28K |
| 2019 | -25.59% | 0.00% | 0.00x | 1.03x | $-140.47K |
| 2020 | -134.25% | 0.00% | 0.00x | 1.18x | $-2.09 Million |
| 2021 | -2225.14% | -3729.17% | 0.50x | 1.18x | $-32.36 Million |
| 2022 | -82.94% | 0.00% | 0.00x | 1.07x | $-80.04 Million |
| 2023 | -52.57% | 0.00% | 0.00x | 1.10x | $-47.65 Million |
| 2024 | -26.75% | 0.00% | 0.00x | 1.03x | $-107.27 Million |
| 2025 | -47.70% | 0.00% | 0.00x | 1.09x | $-136.86 Million |
Industry Comparison
This section compares Cybin Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cybin Inc (CYBN) | $139.00 Million | -43.38% | 0.30x | $202.22 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |